Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The clinical leap is not established
What is missing There is no published human pharmacokinetic study of subcutaneous AOD-9604, no published human topical or intranasal exposure data, no Phase 3 efficacy trial, no long-term safety data beyond 24 weeks, and no published human cartilage or joint outcome data
Syra Aesthetics & Longevity Institute in Manhattan, peptide therapy is offered as part of a personalized longevity and wellness approach
While the main reason for BPC-157s popularity is its potential for speeding up recovery, there is no evidence that the peptide can exert any of these effects in humans
US$ 27.85
US$ 21.28
US$ 27.96
